Skip to main content

Table 2 Cox proportional hazard model of all-cause mortality (event = 142/ n = 497)

From: Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation

Risk factor

Univariable

Multivariable

HR

95% Cl

P value

HR

95% Cl

P value

Age

1.045

1.028–1.063

< 0.001

1.025

1.007–1.044

0.007

Male sex

1.044

0.741–1.472

0.805

   

NYHA class III or IV

4.662

2.718–7.995

< 0.001

1.561

0.826–2.949

0.170

Ischemic etiology

1.031

0.682–1.560

0.885

   

Preserved LVEF

0.770

0.552–1.073

0.122

   

Hypertension

1.089

0.719–1.651

0.687

   

Diabetes

1.331

0.957–1.851

0.089

   

Chronic kidney disease

1.842

1.274–2.664

0.001

1.352

0.899–2.032

0.147

Anemia

2.456

1.688–3.573

< 0.001

1.849

1.214–2.816

0.004

Hyponatremia

2.089

1.346–3.241

0.001

1.406

0.890–2.222

0.144

Log BNP

3.541

2.394–5.238

< 0.001

2.970

1.903–4.635

< 0.001

RAS inhibitors

0.632

0.433–0.921

0.017

0.750

0.492–1.141

0.179

β-blockers

0.636

0.437–0.927

0.018

0.657

0.426–1.014

0.058

Diuretics

2.290

1.379–3.802

0.001

2.008

1.137–3.546

0.016

Inotropic agents

2.026

1.377–2.982

< 0.001

2.126

1.366–2.308

0.001

Anticoagulants: Non

Ref

  

Ref

  

      VKAs

0.493

0.335–0.725

< 0.001

0.472

0.296–0.750

0.002

      DOACs

0.352

0.210–0.590

< 0.001

0.356

0.199–0.638

0.001

  1. NYHA New York Heart Association, LVEF left ventricular ejection fraction, BNP B-type natriuretic peptide, RAS renin-angiotensin-aldosterone system, VKAs vitamin K antagonists, DOACs direct oral anti-coagulants
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us